Dian Diagnostics GroupLtd Gelecekteki Büyüme

Future kriter kontrolleri 3/6

Dian Diagnostics GroupLtd kazanç ve gelirin sırasıyla yıllık 81.9% ve 8.2% oranında artacağı tahmin edilmektedir. EPS'nin yıllık 81.6% oranında büyümesi beklenmektedir. Özkaynak kârlılığının 3 yıl içinde 7.6% olacağı tahmin edilmektedir.

Anahtar bilgiler

81.9%

Kazanç büyüme oranı

81.6%

EPS büyüme oranı

Healthcare kazanç büyümesi	23.2%
Gelir büyüme oranı	8.2%
Gelecekteki özkaynak getirisi	7.6%
Analist kapsamı	Good
Son güncelleme	04 Nov 2024

Gelecekteki son büyüme güncellemeleri

Dian Diagnostics Group Co.,Ltd. Just Missed Earnings - But Analysts Have Updated Their Models

Apr 30

Recent updates

Dian Diagnostics Group Co.,Ltd.'s (SZSE:300244) Shares Bounce 37% But Its Business Still Trails The Industry

Oct 04

Dian Diagnostics Group Co.,Ltd. (SZSE:300244) Looks Inexpensive But Perhaps Not Attractive Enough

Aug 20

Returns On Capital Signal Tricky Times Ahead For Dian Diagnostics GroupLtd (SZSE:300244)

Jul 12

Dian Diagnostics GroupLtd (SZSE:300244) Will Pay A Smaller Dividend Than Last Year

Jun 10

Dian Diagnostics GroupLtd (SZSE:300244) Seems To Use Debt Quite Sensibly

May 24

Dian Diagnostics Group Co.,Ltd. Just Missed Earnings - But Analysts Have Updated Their Models

Apr 30

Investors Holding Back On Dian Diagnostics Group Co.,Ltd. (SZSE:300244)

Apr 22

Kazanç ve Gelir Büyüme Tahminleri

SZSE:300244 - Analistlerin gelecek tahminleri ve geçmiş finansal verileri (CNY Millions )
Tarih	Gelir	Kazançlar	Serbest Nakit Akışı	Faaliyetlerden Nakit	Avg. Analist Sayısı
12/31/2026	14,826	745	1,049	1,908	10
12/31/2025	13,648	576	903	1,601	11
12/31/2024	12,567	274	1,212	1,817	10
9/30/2024	12,374	-93	1,105	1,609	N/A
6/30/2024	12,785	-74	1,074	1,615	N/A
3/31/2024	13,150	170	1,263	1,883	N/A
12/31/2023	13,408	307	1,220	1,921	N/A
9/30/2023	14,945	-463	1,065	1,954	N/A
6/30/2023	16,371	8	1,376	2,239	N/A
3/31/2023	18,865	841	1,444	2,384	N/A
1/1/2023	20,282	1,434	692	1,639	N/A
9/30/2022	19,374	2,358	173	897	N/A
6/30/2022	18,045	2,316	-124	627	N/A
3/31/2022	14,863	1,578	102	756	N/A
1/1/2022	13,083	1,163	728	1,318	N/A
9/30/2021	12,515	1,136	1,050	1,591	N/A
6/30/2021	11,967	1,029	1,115	1,646	N/A
3/31/2021	11,985	1,135	946	1,456	N/A
12/31/2020	10,649	803	1,072	1,547	N/A
9/30/2020	9,716	895	407	780	N/A
6/30/2020	8,932	601	221	552	N/A
3/31/2020	8,150	281	99	409	N/A
12/31/2019	8,453	347	72	483	N/A
9/30/2019	8,291	448	164	602	N/A
6/30/2019	8,006	433	-2	471	N/A
3/31/2019	7,593	398	-97	423	N/A
12/31/2018	6,967	389	-83	373	N/A
9/30/2018	6,214	392	-299	140	N/A
6/30/2018	5,640	373	N/A	31	N/A
3/31/2018	5,169	356	N/A	-49	N/A
12/31/2017	5,004	350	N/A	39	N/A
9/30/2017	4,903	325	N/A	-79	N/A
6/30/2017	4,515	308	N/A	-46	N/A
3/31/2017	4,233	279	N/A	21	N/A
12/31/2016	3,824	263	N/A	132	N/A
9/30/2016	3,147	238	N/A	67	N/A
6/30/2016	2,673	221	N/A	93	N/A
3/31/2016	2,165	188	N/A	84	N/A
12/31/2015	1,858	175	N/A	131	N/A
9/30/2015	1,645	161	N/A	137	N/A
6/30/2015	1,523	151	N/A	160	N/A
3/31/2015	1,411	132	N/A	85	N/A
12/31/2014	1,335	125	N/A	118	N/A
9/30/2014	1,275	113	N/A	123	N/A
6/30/2014	1,178	103	N/A	121	N/A
3/31/2014	1,082	90	N/A	97	N/A
12/31/2013	1,015	86	N/A	75	N/A

Analist Gelecek Büyüme Tahminleri

Kazançlar ve Tasarruf Oranları: 300244 önümüzdeki 3 yıl içerisinde kârlı hale gelmesi öngörülüyor; bu da tasarruf oranından ( 2.8% ) daha hızlı bir büyüme olarak değerlendiriliyor.

Kazançlar ve Piyasa: 300244 önümüzdeki 3 yıl içerisinde karlı hale gelmesi öngörülüyor ki bu da ortalama piyasa büyümesinin üzerinde kabul ediliyor.

Yüksek Büyüme Kazançları: 300244 önümüzdeki 3 yıl içinde karlı hale gelmesi bekleniyor.

Gelir ve Pazar: 300244 şirketinin gelirinin (yıllık 8.2% ) CN pazarından (yıllık 13.8% ) daha yavaş büyümesi öngörülüyor.

Yüksek Büyüme Geliri: 300244 şirketinin gelirinin (yıllık 8.2% ) yıllık 20% oranından daha yavaş büyümesi öngörülüyor.

Hisse Başına Kazanç Büyüme Tahminleri

Gelecekteki Özkaynak Getirisi

Gelecekteki ROE: 300244 'nin Özsermaye Getirisi'nin 3 yıl içinde düşük olması tahmin ediliyor ( 7.6 %).

Dian Diagnostics GroupLtd Gelecekteki Büyüme

Future kriter kontrolleri 3/6

Anahtar bilgiler

Gelecekteki son büyüme güncellemeleri

Price target decreased by 15% to CN¥13.76

Price target decreased by 7.5% to CN¥25.72

Consensus EPS estimates fall by 43%

Dian Diagnostics Group Co.,Ltd. Just Missed Earnings - But Analysts Have Updated Their Models

Price target decreased by 8.3% to CN¥28.27

Price target decreased by 9.9% to CN¥31.56

Recent updates

Third quarter 2024 earnings: EPS and revenues miss analyst expectations

Dian Diagnostics Group Co.,Ltd.'s (SZSE:300244) Shares Bounce 37% But Its Business Still Trails The Industry

Dian Diagnostics Group Co.,Ltd. to Report Q3, 2024 Results on Oct 24, 2024

New minor risk - Share price stability

Dian Diagnostics Group Co.,Ltd. Approves Interim Cash Dividend for the Year 2024, Payable on September 20, 2024

Dian Diagnostics Group Co.,Ltd. Approves Interim Cash Dividend for the Year 2024

Price target decreased by 15% to CN¥13.76

Second quarter 2024 earnings: EPS and revenues miss analyst expectations

Dian Diagnostics Group Co.,Ltd. (SZSE:300244) Looks Inexpensive But Perhaps Not Attractive Enough

Returns On Capital Signal Tricky Times Ahead For Dian Diagnostics GroupLtd (SZSE:300244)

Dian Diagnostics Group Co.,Ltd. to Report First Half, 2024 Results on Aug 29, 2024

Dian Diagnostics GroupLtd (SZSE:300244) Will Pay A Smaller Dividend Than Last Year

Dividend reduced to CN¥0.06

Dian Diagnostics Group Co.,Ltd. Announces Dividend on share A for the Year 2023, Payable on June 13, 2024

Dian Diagnostics GroupLtd (SZSE:300244) Seems To Use Debt Quite Sensibly

Price target decreased by 7.5% to CN¥25.72

Consensus EPS estimates fall by 43%

Dian Diagnostics Group Co.,Ltd. Just Missed Earnings - But Analysts Have Updated Their Models

Investors Holding Back On Dian Diagnostics Group Co.,Ltd. (SZSE:300244)

Dian Diagnostics Group Co.,Ltd., Annual General Meeting, May 20, 2024

Full year 2023 earnings: EPS and revenues miss analyst expectations

Price target decreased by 8.3% to CN¥28.27

Dian Diagnostics Group Co.,Ltd. to Report Q1, 2024 Results on Apr 27, 2024

Dian Diagnostics Group Co.,Ltd. to Report Fiscal Year 2023 Results on Apr 20, 2024

Dian Diagnostics Group Co.,Ltd. Announces Executive Appointments

Price target decreased by 9.9% to CN¥31.56

Third quarter 2023 earnings: EPS misses analyst expectations

Consensus EPS estimates fall by 20%

Price target decreased by 8.0% to CN¥37.35

Second quarter 2023 earnings: EPS and revenues miss analyst expectations

Now 20% undervalued after recent price drop

Dian Diagnostics Group Co.,Ltd. Announces Final Cash Dividend for A Shares, Payable on 31 May 2023

Dian Diagnostics Group Co.,Ltd. Approves Cash Dividend for 2022

Price target decreased by 10% to CN¥38.72

Full year 2022 earnings: Revenues exceed analysts expectations while EPS lags behind

Investor sentiment improves as stock rises 18%

Consensus EPS estimates fall by 10%, revenue upgraded

Consensus EPS estimates fall by 43%

Dian Diagnostics Group Co.,Ltd. (SZSE:300244) announces an Equity Buyback for CNY 50 million worth of its shares.

Less than half of directors are independent

Consensus revenue estimates increase by 14%

Third quarter 2022 earnings: EPS and revenues exceed analyst expectations

Consensus EPS estimates increase by 14%

Second quarter 2022 earnings: EPS and revenues exceed analyst expectations

Dian Diagnostics Group Co.,Ltd. Announces Final Cash Dividend on A Shares for 2021, Payable on 08 June 2022

Less than half of directors are independent

Dian Diagnostics Group Co.,Ltd. Announces Dividend for 2021

Now 20% undervalued

Investor sentiment improved over the past week

First quarter 2022 earnings: EPS and revenues exceed analyst expectations

Dian Diagnostics Group Co.,Ltd. Proposes Final Cash Dividend for 2021

Full year 2021 earnings: Revenues exceed analysts expectations while EPS lags behind

Now 21% undervalued after recent price drop

Now 23% undervalued after recent price drop

Price target decreased to CN¥48.50

Third quarter 2021 earnings released: EPS CN¥0.81 (vs CN¥0.64 in 3Q 2020)

Second quarter 2021 earnings released: EPS CN¥0.63 (vs CN¥0.80 in 2Q 2020)

Investor sentiment improved over the past week

Price target decreased to CN¥52.85

Dian Diagnostics Group Co.,Ltd. Approved Final Cash Dividend for 2020

First quarter 2021 earnings released: EPS CN¥0.55 (vs CN¥0.011 in 1Q 2020)

Consensus EPS estimates increase to CN¥1.82

Full year 2020 earnings released: EPS CN¥1.29 (vs CN¥0.56 in FY 2019)

New 90-day low: CN¥32.92

Dian Diagnostics Group Co.,Ltd. to Report Fiscal Year 2020 Results on Apr 10, 2021

Investor sentiment deteriorated over the past week

New 90-day high: CN¥43.96

Investor sentiment improved over the past week

Investor sentiment improved over the past week